Coordinating Center for the Pediatric HIV/AIDS Cohort S*

儿科艾滋病毒/艾滋病队列 S 协调中心*

• 批准号: 7652262
• 负责人: RUSSELL B. VAN DYKE
• 金额: $ 58.61万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-30 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7652262
• 关键词: 16 year old; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Address; Adolescence; Adolescent; Area; Behavior; Body Composition; Cardiac; Cardiotoxicity; Centers for Disease Control and Prevention (U.S.); Child; Childhood; Cognitive; Cohort Studies; Collaborations; Complication; Data; Data Coordinating Center; Databases; Development; Disease; Drug toxicity; Endocrinology; Enrollment; Epidemic; Epidemiology; Event; Goals; Growth; Growth and Development function; Gynecologic; Gynecology; HIV; HIV Infections; HIV-1; Human Papillomavirus; Hyperlipidemia; IMPAACT; Individual; Infant; Infection; Leadership; Metabolism; Mitochondrial Diseases; Monitor; Newborn Infant; Operative Surgical Procedures; Organ; Outcome; Performance; Perinatal; Pharmaceutical Preparations; Pharmacoepidemiology; Phase; Policies; Population; Preventive; Principal Investigator; Procedures; Protocols documentation; Puberty; Recruitment Activity; Research Design; Research Infrastructure; Research Personnel; Rewards; Risk Assessment; Safety; Sexual Maturation; Social Functioning; Socialization; Specific qualifier value; Structure; System; To specify; Toxic effect; Vertical Disease Transmission; Woman; Work; antiretroviral therapy; base; cardiovascular risk factor; clinical research site; cohort; experience; follow-up; in utero; member; mitochondrial dysfunction; neonatal exposure; neuropsychological; nutrition; organizational structure; pediatric human immunodeficiency virus; pediatric human immunodeficiency virus infection; prevent; programs; reproductive; transmission process

DESCRIPTION (provided by applicant): The Coordinating Center (CC) of the PHACS consists of the PI, project director, and a group of leading investigators comprising the Scientific Leadership Group (SLG). Together with the Data Operations Center, the CC will establish the leadership structure of the PHACS including an Executive Committee (EC), an External Oversight Committee, and the SLG. The EC will be the main governing body of the PHACS and will provide oversight and final approval for all group activities. The CC will be responsible for overall management of the PHACS. The SLG will be responsible for defining the scientific agenda of the PHACS and, during year 1, the development of the two protocols which will address this agenda, each with its own cohort of subjects, specific objectives, and sub-studies. The Drug Toxicity Surveillance System will evaluate the safety of preventive antiretroviral therapy when administered to HIV-exposed infants in utero and in the newborn period. This will be an open protocol with ongoing accrual; initially subjects will be enrolled from the WITS and PACTG 219c studies. It will generate a cohort of HIV-uninfected children who will be monitored longitudinally for the development of mitochondrial disease, abnormalities in growth and development, and other end-organ disease. The Base Protocol will address the impact of HIV-infection on sexual maturation, pubertal development, and socialization of perinatally HIV-infected preadolescents and adolescents and define the course of perinatal HIV infection during adolescence. It will be a closed cohort, consisting of subjects 7-16 years of age who were previously enrolled in WITS and 219c. The Base Protocol will be fully coordinated with the CDC Legacy Project in order to expand the population available to study uncommon events. Once the protocols are developed in year one, a variety of focused sub-studies, utilizing one or both of the cohorts, will be developed by the SLG in order to address a variety of specific scientific questions. For the Base Protocol cohort, these include: neurodevelopmental and academic/vocational outcomes; changes in growth, development, body composition, and metabolism; mitochondrial disease and other toxicities resulting from ART; hyperlipidemias, other cardiac risk factors, and cardiovascular complications; reproductive and gynecologic outcomes and HPV infections; and infectious and non-infectious complications of HIV infection.

描述（由申请人提供）：PHACS的协调中心（CC）由PI、项目负责人和一组主要研究者组成，包括科学领导小组（SLG）。CC将与数据运营中心一起建立PHACS的领导结构，包括执行委员会（EC），外部监督委员会和SLG。EC将是PHACS的主要管理机构，并将为所有小组活动提供监督和最终批准。协调委员会将负责PHACS的整体管理。SLG将负责确定PHACS的科学议程，并在第一年制定两项方案，以解决这一议程，每项方案都有自己的受试者队列，具体目标和子研究。药物毒性监测系统将评价预防性抗逆转录病毒治疗对宫内和新生儿期艾滋病毒感染婴儿的安全性。这将是一项开放方案，持续招募;最初受试者将从WITS和PACTG 219 c研究中入组。它将产生一组未感染艾滋病毒的儿童，他们将被纵向监测线粒体疾病、生长发育异常和其他终末器官疾病的发展。基础协议将解决艾滋病毒感染对性成熟，青春期发育和社会化的围产期艾滋病毒感染的青春期前和青少年的影响，并确定青春期围产期艾滋病毒感染的过程。这将是一个封闭队列，由之前入组WITS和219 c的7-16岁受试者组成。基础方案将与CDC遗留项目充分协调，以扩大可用于研究罕见事件的人群。一旦在第一年制定了方案，SLG将利用一个或两个队列开发各种重点子研究，以解决各种具体的科学问题。对于基础方案队列，这些包括：神经发育和学术/职业结局;生长、发育、身体组成和代谢的变化;线粒体疾病和ART引起的其他毒性;高血压、其他心脏风险因素和心血管并发症;生殖和妇科结局和HPV感染;以及HIV感染的感染性和非感染性并发症。